Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab in Paediatric Patients for the Preventive Treatment of Episodic Migraine
NCT05897320Phase 3Recruiting
- Sponsor
- Lundbeck
- Start
- Jun 2023
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of eptinezumab, sponsored by Lundbeck. Started Jun 2023; status: recruiting.
02
Drugs
eptinezumab
Beyond the preview
Go deeper on NCT05897320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05897320.